A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Vismodegib (Primary) ; Pirfenidone
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Roche
- 17 Feb 2017 Status changed from recruiting to completed.
- 01 Jul 2016 Planned End Date changed from 1 May 2017 to 1 Dec 2016.
- 01 Jul 2016 Planned primary completion date changed from 1 May 2017 to 1 Dec 2016.